{Reference Type}: Journal Article
{Title}: Escalating Plasmodium falciparum K13 marker prevalence indicative of artemisinin resistance in southern Rwanda.
{Author}: van Loon W;Schallenberg E;Igiraneza C;Habarugira F;Mbarushimana D;Nshimiyimana F;Ngarambe C;Ntihumbya JB;Ndoli JM;Mockenhaupt FP;
{Journal}: Antimicrob Agents Chemother
{Volume}: 68
{Issue}: 1
{Year}: 2024 Jan 10
{Factor}: 5.938
{DOI}: 10.1128/aac.01299-23
{Abstract}: In 2023, we updated data collected since 2010 on Plasmodium falciparum K13 and MDR1 drug resistance markers in Huye district, southern Rwanda. Artemisinin resistance-associated PfK13 markers occurred in 17.5% of 212 malaria patients (561H, 9.0%; 675V, 5.7%; and 469F, 2.8%), nearly double the frequency from 2019. PfMDR1 N86, linked with lumefantrine tolerance, was close to fixation at 98%. In southern Rwanda, markers signaling resistance to artemisinin and lumefantrine are increasing, albeit at a relatively slow rate.